- $722.30m
- $513.05m
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Annexon, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
U.S. STOCKS ON THE MOVE-Nebius Group, Lumentum Holdings
Annexon falls on bigger-than-expected quarterly loss
Annexon Biosciences Q2 net loss widens, cash runway extended
Brief: Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)
Annexon Biosciences Q1 net loss narrows as expenses decline
Brief: Annexon Reports Inducement Grant To New Employee Under Nasdaq Listing Rule 5635(C)(4)
Brief: Annexon Submits Tanruprubart Marketing Authorization Application To The European Medicines Agency For Guillain-Barré Syndrome
U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA
Drug developer Annexon slips after $75 million capital raise
Brief: Annexon Prices Public Offering Of 25,096,153 Shares At $2.60 Each
Brief: Annexon Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Annexon Q3 net loss widens to $54.9 mln
Brief: Annexon Reports Inducement Grant To New Employee Under Nasdaq Listing Rule 5635(C)(4)
Annexon Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025